首页> 外文期刊>Scandinavian journal of immunology. >Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study
【24h】

Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study

机译:基于表位的肽疫苗设计和针对埃博拉病毒的靶位点描述:一项免疫信息学研究

获取原文
获取原文并翻译 | 示例
       

摘要

Ebola viruses (EBOVs) have been identified as an emerging threat in recent year as it causes severe haemorrhagic fever in human. Epitope-based vaccine design for EBOVs remains a top priority because a mere progress has been made in this regard. Another reason is the lack of antiviral drug and licensed vaccine although there is a severe outbreak in Central Africa. In this study, we aimed to design an epitope-based vaccine that can trigger a significant immune response as well as to prognosticate inhibitor that can bind with potential drug target sites using various immunoinformatics and docking simulation tools. The capacity to induce both humoral and cell-mediated immunity by T cell and B cell was checked for the selected protein. The peptide region spanning 9 amino acids from 42 to 50 and the sequence TLASIGTAF were found as the most potential B and T cell epitopes, respectively. This peptide could interact with 12 HLAs and showed high population coverage up to 80.99%. Using molecular docking, the epitope was further appraised for binding against HLA molecules to verify the binding cleft interaction. In addition with this, the allergenicity of the epitopes was also evaluated. In the post-therapeutic strategy, docking study of predicted 3D structure identified suitable therapeutic inhibitor against targeted protein. However, this computational epitope-based peptide vaccine designing and target site prediction against EBOVs open up a new horizon which may be the prospective way in Ebola viruses research; the results require validation by invitro and invivo experiments.
机译:埃博拉病毒(EBOVs)近年来已被确定为正在出现的威胁,因为它会引起人类严重的出血热。 EBOVs的基于表位的疫苗设计仍然是重中之重,因为在这方面仅取得了进展。另一个原因是尽管中部非洲发生了严重的疫情,但缺乏抗病毒药物和许可疫苗。在这项研究中,我们旨在设计一种基于表位的疫苗,该疫苗可以触发显着的免疫反应,并使用各种免疫信息学和对接模拟工具预测可以与潜在药物靶位点结合的抑制剂。检查所选蛋白质诱导T细胞和B细胞诱导体液和细胞介导的免疫的能力。发现涵盖42至50个9个氨基酸的肽区域和序列TLASIGTAF分别是最有潜力的B和T细胞表位。该肽可与12种HLA相互作用,并显示高达80.99%的高种群覆盖率。使用分子对接,进一步评估表位与HLA分子的结合,以验证结合裂隙相互作用。除此之外,还评估了表位的致敏性。在治疗后策略中,对预测的3D结构的对接研究确定了针对靶蛋白的合适治疗抑制剂。然而,这种基于表位的计算性肽疫苗设计和针对EBOVs的目标位点预测开辟了新的视野,这可能是埃博拉病毒研究的前途。结果需要通过体外和体内实验进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号